- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01284946
Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
A Phase II, Open Label Clinical Trial Exploring the Safety and the Efficacy of Oral Deferasirox in Patients Newly Diagnosed With Porphyria Cutanea Tarda (PCT) and Non-transfusion Iron Overload
Study Overview
Detailed Description
The primary objective is to assess the safety of deferasirox in treating non-transfusion iron overload in patients with PCT.
The secondary objective is to assess the effectiveness of deferasirox treatment :
After 3 and 6 months to:
•Lower serum ferritin from abnormal to normal standard ranges specified for males and females in this patient population.
After 6 months to :
•Lower liver iron content after 24 weeks of treatment measured by liver MRI T2
After 3 and 6 months to :
- Improve clinical symptoms, i.e. improvement in skin lesions (reduction or no new bullae formation), and skin fragility (photographs will be used).
- Reduce porphyrin levels.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Benoit Coffin, Professor
- Phone Number: 33147606061
- Email: benoit.coffin@lmr.aphp.fr
Study Locations
-
-
Ile de France
-
Colombes, Ile de France, France, 92700
- Recruiting
- Hopital Louis Mourier, GI unit,
-
Contact:
- Benoit Coffin, Professor
- Phone Number: 33147606061
- Email: benoit.coffin@lmr.aphp.fr
-
Principal Investigator:
- Deybach Jean-Charles, Professor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male and female diagnosed with clinically overt Porphyria Cutanea Tarda, sporadic or familial as per the European Porphyria Network guidelines i.e. increased urinary and plasma porphyrins and faecal isocoproporphyrin detected by fluorescence emission spectroscopy,
- Skin fragility and bullae lesions,
- Age ≥ 18 years old,
- non-transfusion iron overload as depicted by a serum ferritin value ≥ 300 μg/L for men and ≥ 200 μg/L for women, and/or LIC ≥ 2 mg Fe/g dw for both men and women and with transferrin saturation ≥ 45%,
- Adequate liver function i.e. ALAT/ASAT and Alkaline Phosphatase ? 2.5 times ULN, bilirubin < 1.5 times ULN,
- Signed informed consent prior to beginning the specific procedures of the protocol,
- Ability to comply with all study-related procedures, medications, and evaluations,
- Sexually active women must use an effective method of contraception, or must have undergone clinically documented total hysterectomy and/or oophorectomy, or tubal ligation or be postmenopausal (defined as amenorrhea for at least 12 months). Since hormonal therapy may cause PCT, oral contraceptives will not be started during the course of the study and patients already on oral contraceptives will be advised to speak to their physician about discontinuing them and will not be enrolled in the study.
Exclusion Criteria:
Clinical evidence of active Hepatitis B (positive HBsAg with negative HBsAb) and/or hepatitis C (positive HCV antibody and detectable HCV RNA with ALT above the normal range)
- Patients with on going alcoholic dependency > 60g/day
- Serum creatinine above the ULN
- Creatinine clearance < 60 ml/min, estimated according to Cockcroft-Gault formula or MDRD formula for adults
- Significant proteinuria as indicated by a urine protein: urine creatinine ratio > 0.5 mg/mg in a non-first void urine sample.
- Diabetes
- Iron overload due to hereditary hemochromatosis
- History of blood transfusion during the 6 months prior to study entry,
- Males with hemoglobin <13 mg/dL, females with hemoglobin <12 mg/dL
- Active peptic ulcus
- Treatment with phlebotomy within 2 weeks of screening visit
- Prior Desferal® treatment within 1 month of the screening visit
- Patients currently or previously treated with deferiprone or deferasirox
- Patients with a diagnosis of a clinically relevant cataract or a previous history of clinically relevant ocular toxicity related to iron chelation
- Patient with clinically significant decrease of hearing
- Pregnant or lactating women or women of childbearing potential not using adequate contraception (pregnancy test mandatory and negative for patient with childbearing potential)
- Known hypersensitivity to the active ingredient of deferasirox or any excipients
- Contraindication to the administration of deferasirox as outlined in the approved prescribing information.
- Presence of a surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of deferasirox
- Presence of a non-controlled severe disease affected vital organs as cardiac and/or pulmonary disease
- Patients with a known diagnosis of cirrhosis (confirmed by biopsy)
- Patients with active inflammatory diseases that may interfere with the accurate measurement of serum ferritin
- Patients treated with systemic investigational drug within 4 weeks prior or with topical investigational drug within 7 days prior to the screening visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exjade
Safety and efficacy
|
Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary objective is to assess the safety of deferasirox in treating non-transfusion iron overload in patients with PCT.
Time Frame: 6 months
|
6 months
|
|
Related drug adverse events
Time Frame: 6 months
|
Incidence type and severity of drug related adverse events
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change from baseline in serum ferritin after 12 and 24 weeks of treatment,The change from baseline in iron burden after 24 weeks of treatment measured by liver MRI T2,The evolution of clinical symptoms
Time Frame: 6 months
|
6 months
|
Chage from baseline in serum ferritin, iron burden, improvement in clincal symptoms, porphyrin levels
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Deybach Jean-Charles, Professor, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Metabolic Diseases
- Skin Diseases
- Liver Diseases
- Genetic Diseases, Inborn
- Skin Diseases, Genetic
- Porphyria Cutanea Tarda
- Porphyrias, Hepatic
- Porphyria, Erythropoietic
- Porphyrias
- Molecular Mechanisms of Pharmacological Action
- Chelating Agents
- Sequestering Agents
- Iron Chelating Agents
- Deferasirox
Other Study ID Numbers
- AEFD2010-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Porphyria Cutanea Tarda
-
University of Texas Southwestern Medical CenterNovartis PharmaceuticalsCompletedPorphyria Cutanea TardaUnited States
-
University Hospital, Strasbourg, FranceCompletedPorphyria Cutanea Tarda
-
The University of Texas Medical Branch, GalvestonCompletedPorphyria Cutanea TardaUnited States
-
National Center for Research Resources (NCRR)University of TexasCompleted
-
National Institute of Cardiology, Warsaw, PolandInstitute of Hematology and Transfusion Medicine, WarsawCompletedPorphyrias, HepaticPoland
-
Wake Forest University Health SciencesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Gilead... and other collaboratorsCompleted
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsCompletedAcute Intermittent Porphyria (AIP) | Hereditary Coproporphyria (HCP) | Variegate Porphyria (VP)United States
-
The University of Texas Medical Branch, GalvestonTerminatedHereditary Coproporphyria | Acute Intermittent Porphyria | Variegate PorphyriaUnited States
-
Alnylam PharmaceuticalsTerminatedAcute Hepatic Porphyria | Acute Intermittent Porphyria (AIP) | Hereditary Coproporphyria (HCP) | Variegate Porphyria (VP) | ALA Dehydratase Deficient Porphyria (ADP) | Hepatic Porphyrias | Porphyria AcuteUnited States
-
Alnylam PharmaceuticalsCompletedAcute Hepatic Porphyria | Acute Intermittent Porphyria | Porphyria, Acute Intermittent | Acute Porphyria | Hereditary Coproporphyria (HCP) | Variegate Porphyria (VP) | ALA Dehydratase Deficient Porphyria (ADP)United States, Spain, United Kingdom, Korea, Republic of, Australia, Bulgaria, Canada, Denmark, Finland, France, Germany, Italy, Japan, Mexico, Netherlands, Poland, Sweden, Taiwan
Clinical Trials on Exjade
-
Elliott VichinskyCompletedIron Overload | ThalassemiaUnited States
-
University Hospital, GrenobleNovartisRecruiting
-
Novartis PharmaceuticalsCompletedTransfusional HemosiderosisUnited States
-
Wolfson Medical CenterHadassah Medical Organization; Tel-Aviv Sourasky Medical Center; Sheba Medical... and other collaboratorsCompletedMyelodysplastic SyndromeIsrael
-
University of Texas Southwestern Medical CenterNovartis PharmaceuticalsCompletedPorphyria Cutanea TardaUnited States
-
Novartis PharmaceuticalsCompletedIron Overload | Hemosiderosis | Beta-thalassemia Major | Rare AnemiaEgypt, Oman, Saudi Arabia, Syrian Arab Republic, Lebanon
-
Fondazione Italiana Sindromi Mielodisplastiche-ETSTerminated
-
Masonic Cancer Center, University of MinnesotaTerminatedLymphoma | Myelodysplastic Syndromes | Leukemia | Breast Cancer | Iron Overload | Ovarian Cancer | Neuroblastoma | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
City of Hope Medical CenterTerminatedPrimary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Iron Overload | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell... and other conditionsUnited States
-
Crolll GmbhUniversity of Magdeburg; Estimate, GmbHCompletedNon-alcoholic Steatohepatitis | Increased Iron Storage / Disturbed DistributionGermany